Sat, Apr 19, 2014, 8:47 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • biotechal biotechal Jan 3, 2013 7:48 AM Flag

    IGXT (Mcap $32 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013= 1000%++ Potential

     

    A REAL ONCE IN A LIFETIME OPPORTUNITY HERE.. Please do your own dd to realize the Mega Potential .GL

    Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by mid 2013 because of its very low burn-rate of only $1.2 Mil a year !

    2x New NDA filings for Migraine and Erectile Dysfunction indication in early 2013 . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .

    IGXT has NO DEBT and current Market cap of only $32 M is really a BIG BIG BARGAIN .

    My Target is $8-12 within 2 Years .GLTA

    Intelgenx (IGXT.OB)

    Market Cap : $ 32 M
    Cash: $ 3 M ( Burn-rate only $1.2 M a year )
    Price : 0.64 $

    Shares Out : 50 M ( 26 M shares are held by Insiders + Institutions)

    "We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "In addition, following the positive pivotal bioequivalence results announced last quarter for our anti-migraine VersaFilm product, we are pleased to confirm that a recent pre-NDA meeting with FDA confirmed that we remain on track to file our 505(b)(2) NDA submission in the first quarter of 2013.

    ....................
    TLSR: What types of healthcare companies are you looking for? Do you lean toward specialty pharma, where you can monetize more quickly? What are your preferences?

    I have at least two investments in this area—is in the FDA's 505(b)(2) pathway, also known as the rapid approval route. This pathway can be used by companies taking an existing drug with hundreds of millions or several billion dollars in sales and porting that drug onto a different delivery technology. Biovail Corp. (now part of Valeant Pharmaceuticals International Inc. [VRX:NYSE]) followed this pathway when it made Wellbutrin XL, a one-a-day version of Wellbutrin (bupropion hydrochloride). IntelGenx (IGX:TSX.V; IGXT:OTCQX) is my poster child in this area, with eight drugs in various stages of the 505(b)(2) approval process, and one 505(b)(2) drug that will be commercially launched this fall, having received FDA approval in November 2011.

    TLSR: What's the next company you'd like to talk about?

    HC: IntelGenx is the company through which I learned about the 505(b)(2) pathway, and why that pathway is so attractive to me. It's a drug delivery company that takes existing, commercialized drugs and ports them onto different delivery modalities, making them better from a patient compliance perspective or from a time-to-onset-of-action perspective. The existing drugs the company is working with have commercial revenues in the hundreds of millions to several billion-dollar range.

    IntelGenx is about to launch its antidepressant drug, having received FDA approval in November 2011, and has a pipeline of eight drugs being developed via the 505(b)(2) pathway. The company is a table-pounder, simply on the basis that it has an approved drug and a market cap of only $30M. It is truly one of the most dramatic valuation disconnects that I am aware of. Full disclosure: Funds that I manage control about 12% of the company.

    A migraine drug called rizatriptan is a good example of one of IntelGenx's pipeline drug applications. The time to onset of action of a migraine medication is very important. If the medication is delivered in time, it can cut a migraine off at its knees and save the patient from an ugly 12–36 hours. On the other hand, if a patient pops a pill and it takes 45 minutes to kick in, a migraine may get the foothold it needs to overwhelm the medication.

    IntelGenx is moving rizatriptan onto a thin film strip. The time to onset of action for a drug delivered via sublingual strip is much faster than for the pill form. Annual sales of prescription migraine drugs on a global basis are probably more than $5B; annual sales of rizatriptan were over $600M in 2011. If IntelGenx can introduce a better form of the drug, cutting the time to onset of action in half or more—or even if the film cuts it by a third—doctors and patients will be very attracted. IntelGenx's drug could gain market share quickly in the migraine medication area. In another example, the company is moving an erectile dysfunction drug onto a strip. You can imagine reasons you may want quicker onset of action with that.

    The bottom line from an investor perspective is that, as of the close on Aug. 3, 2012, the stock is lower than it was before the company's antidepressant received FDA approval on Nov. 11, 2011; lower than it was before its December 2011 codevelopment and commercialization deal with Par Pharmaceutical Inc.; and lower than it was before the announcement of a commercialization partner for its antidepressant. I would argue that at $0.80 or lower, the only thing an investor is paying for is the antidepressant, meaning that you are getting the entire thin-film delivery platform and eight pipeline drugs for free.

    I suggest that investors check out the analyst report published two weeks ago by Ram Selvaraju of Aegis Capital Corp., initiating coverage on IntelGenx with a $2.50/share, 18-month target. Ram is known as one of the few analysts willing to pick up coverage on sub-$50M market cap companies—as long as he thinks that he can make investors significant returns. One of his more notable sub-$50M initiations was Amarin, back in 2009, when it had a market cap of about $40M.

    .......................

    This topic is deleted.
 
MNTA
11.10-0.46(-3.98%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.